Research library / Multivitamins
BB Good human data, but mixed outcomes or surrogate markers. How we grade →RCT (double-blind, 2-by-2 factorial) · 21,442 US adults (12,666 women aged 65+, 8,776 men aged 60+), median 3.6 years
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial
H Sesso, P Rist, A Aragaki, S Rautiainen, L Johnson, G Friedenberg et al. The American Journal of Clinical Nutrition. 2022.
- In plain language
- COSMOS: a daily multivitamin did not significantly reduce the composite cardiovascular outcome (429 vs 437 events, HR 0.98, 95% CI 0.86 to 1.12), which includes heart attacks and strokes.
- Limits
- One product (Centrum Silver); mostly white, health-conscious older adults; pills supplied by Pfizer/GSK and cocoa extract by Mars Edge; median follow-up 3.6 years.
- Which of our grades it feeds
- CC Small or few human trials. Promising, not proven. How we grade →Ratings card: Daily multivitamin: Filling common nutrient gaps
- Source
- doi.org/10.1093/ajcn/nqac056 · PubMed 35294969
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.